![]() Purdue Pharma’ opens with a group led by Dr. Whether or not there was an explicit quid pro quo agreement between Wright and Purdue Pharma, the revolving door system often led regulators like Wright to become friendly with the industry, lest they cost themselves a future payday. Wright reportedly made $400,000 in his first year at Purdue–shocking, but all part of the legal gray area of the pharmaceutical industry.However, does justice prevail? Or is Purdue once again able to buy its way out of facing the consequences of its actions? Here’s everything that happens in ‘Dopesick’ episode 8, along with answers to some of the show’s burning questions. Another FDA employee explains that this is " the way it works," describing the common practice of people in the FDA and other government agencies leaving to work for the very companies they had once regulated. In Dopesick, Ramseyer and Mountcastle learn this in an interview scene reminiscent of investigative thrillers like Spotlight. It's exactly the intentionally vague nature and extremely careful wording of the label that led doctors to trust what they were being told.īringing an air of corruption into the story is the fact that just two years after waving through Ox圜ontin and the misleading label, despite zero evidence to support it, Wright left the FDA and shortly afterward began working at Purdue Pharma in a high-level, six-figure job. Wright testified that he did not remember who wrote the label, but downplayed its significance, claiming, “ The label makes an extremely weak statement about a class of drugs.” (via Marketplace) It is true that the statement uses plenty of hedging language, most notably "is believed to reduce," but its unusual nature was taken as evidence that the FDA had demonstrable proof that Ox圜ontin was less addictive than traditional painkillers. In real life, the exact authorship of the label has been debated in court, with Purdue suggesting that the FDA added it of their own accord. However, Purdue had conducted no actual studies to support this claim, and Wright knew it. In Dopesick, FDA employees also confirm the person who approved of this label was Curtis Wright. Particular focus has fallen on a special label issued by the FDA specifically for Ox圜ontin which read “ Delayed absorption as provided by Ox圜ontin tablets is believed to reduce the abuse liability of a drug.” As depicted in Dopesick, this label was used by sales representatives to sell Ox圜ontin as a treatment for moderate pain, to skeptical doctors like the one played by former Batman star Michael Keaton. In this position, Wright played a key role in allowing the deceptive marketing that suggested Ox圜ontin was non-addictive. ![]() Related: The 25 Best Movies On Hulu Right NowĬurtis Wright was the FDA's deputy director overseeing anesthetics and addiction products during the time Ox圜ontin was being approved. Though Wright does not appear, his name comes up repeatedly in conjunction with potential corruption and the FDA exec that rubber-stamped the aggressive marketing of Ox圜ontin. Curtis Wright's name first comes up when DoJ agents Rick Mountcastle and Randy Ramseyer (played in Dopesick's cast of characters by Peter Sarsgaard and John Hoogenaker, respectively) begin investigating the rise of Ox圜ontin. Dopesick examines the opioid crisis, driven by the drug Ox圜ontin, over a period of two decades from different perspectives, ranging from executives at Purdue Pharma, the makers of Oxy, to individual users in an Appalachian mining town.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |